Danaher Asset write-downs decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $15.00M to $0.00. This is a positive signal — lower values indicate better performance for this metric.
High impairment charges suggest poor past investment decisions or deteriorating market conditions for specific business units.
These are non-cash charges recognized when the carrying value of an asset exceeds its fair market value. They indicate t...
Common in insurance and financial services during economic downturns; peers will report these when asset valuations decline.
operating_asset_impairment_charges| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $35.00M | $0.00 | $0.00 | $222.00M | $43.00M | $15.00M | $432.00M | $101.00M | $14.00M | $0.00 |
| QoQ Change | — | — | — | — | — | -100.0% | — | — | -80.6% | -65.1% | >999% | -76.6% | -86.1% | -100.0% |
| YoY Change | — | — | — | — | — | — | — | — | +22.9% | — | — | -54.5% | -67.4% | -100.0% |
| Segment | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Life Sciences | $0.00 | $0.00 | $0.00 | $0.00 | $432.00M | — | — | $14.00M |
| Biotechnology | $13.50M | $13.50M | $13.50M | $0.00 | $15.00M | $0.00 | $86.00M | — |
| Biotechnology and Diagnostics | $19.25M | $19.25M | $19.25M | — | — | — | — | — |
| Diagnostics | $5.75M | $5.75M | $5.75M | $0.00 | — | — | — | — |
| Total | — | — | $35.00M | $222.00M | $15.00M | $432.00M | $101.00M | $14.00M |
Life Sciences, Biotechnology and Diagnostics Segment is derived from annual filings.
Biotechnology, Biotechnology and Diagnostics, Diagnostics, Life Sciences were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.